Misplaced Pages

Trevogrumab

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Monoclonal antibody Pharmaceutical compound
Trevogrumab
Monoclonal antibody
Type?
SourceHuman
Targetgrowth differentiation factor 8
Clinical data
Other namesREGN1033
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6374H9884N1696O2018S46
Molar mass144037.80 g·mol

Trevogrumab (INN; development code REGN1033) is a human monoclonal antibody designed for the treatment of muscle atrophy due to orthopedic disuse and sarcopenia.

This drug was developed by Regeneron Pharmaceuticals, Inc.

References

  1. World Health Organization (2015). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 113" (PDF). WHO Drug Information. 29 (2).
  2. Statement On A Nonproprietary Name Adopted By The USAN Council - Trevogrumab, American Medical Association.
Stub icon

This monoclonal antibody–related article is a stub. You can help Misplaced Pages by expanding it.

Monoclonals for bone, musculoskeletal, circulatory, and neurologic systems
Bone
Human
Humanized
Musculoskeletal
Human
Circulatory
Human
Mouse
Chimeric
Humanized
Neurologic
Human
Humanized
Angiogenesis inhibitor
Humanized
Growth factor
Human
Humanized
Categories: